Berberine inhibits fluphenazine-induced up-regulation of CDR1 in Candida albicans

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 2, 2014, Pages 268-273

  Zhu, Shao Long ^a,b   Yan, Lan ^a   Zhang, Yan Xia ^c   Jiang, Zhi Hui ^a   Gao, Ping Hui ^a   Qiu, Yue ^b   Wang, Liang ^a   Zhao, Ming Zhu ^a   Ni, Ting Jun Hong ^a   Cai, Zhan ^a   Tian, Shu Juan ^a   Zang, Cheng Xu ^a   Zhang, Da Zhi ^a   Jiang, Yuan Ying ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b 401 Hospital of PLA   (China)

^c FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Berberine; Candida albicans; CDR1; Drug responsive element; Fluphenazine

Indexed keywords

ANTIFUNGAL AGENTS; BERBERINE; CANDIDA ALBICANS; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; FLUPHENAZINE; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; MEMBRANE TRANSPORT PROTEINS; PLANT EXTRACTS; RNA, MESSENGER; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84893217266     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00734     Document Type: Article

References (34)

1. Garber G. An overview of fungal infections. Drugs, 61 (Suppl. 1), 1-12 (2001).
2. Maertens J, Vrebos M, Boogaerts M. Assessing risk factors for systemic fungal infections. Eur. J. Cancer Care (Engl.), 10, 56-62 (2001).
3. Richardson MD. Changing patterns and trends in systemic fungal infections. J. Antimicrob. Chemother., 56 (Suppl. 1), i5-i11 (2005).
4. Boken DJ, Swindells S, Rinaldi MG. Fluconazole-resistant Candida albicans. Clin. Infect. Dis., 17, 1018-1021 (1993).
5. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev., 11, 382-402 (1998).
6. Du W, Coaker M, Sobel JD, Akins RA. Shuttle vectors for Candida albicans. control of plasmid copy number and elevated expression of cloned genes. Curr. Genet., 45, 390-398 (2004).
7. Jia XM, Ma ZP, Jia Y, Gao PH, Zhang JD, Wang Y, Xu Y, Wang L, Cao YY, Cao YB, Zhang LX, Jiang YY. RTA2, a novel gene involved in azole resistance in Candida albicans. Biochem. Biophys. Res. Commun., 373, 631-636 (2008).
8. Jia XM, Wang Y, Jia Y, Gao PH, Xu YG, Wang L, Cao YY, Cao YB, Zhang LX, Jiang YY. RTA 2 is involved in calcineurin-mediated azole resistance and sphingoid long-chain base release in Candida albicans. Cell. Mol. Life Sci., 66, 122-134 (2009).
9. Prasad R, De Wergifosse P, Goffeau A, Balzi E. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr. Genet., 27, 320-329 (1995).
10. Sanglard D, Ischer F, Monod M, Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology, 143, 405-416 (1997).
11. Wirsching S, Michel S, Morschhauser J. Targeted gene disruption in Candida albicans wild-type strains. the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. Mol. Microbiol., 36, 856-865 (2000).
12. Yan L, Li M, Cao Y, Gao P, Cao Y, Wang Y, Jiang Y. The alternative oxidase of Candida albicans c auses r educed fluconazole susceptibility. J. Antimicrob. Chemother., 64, 764-773 (2009).
13. Krishnamurthy S, Gupta V, Snehlata P, Prasad R. Characterisation of human steroid hormone transport mediated by Cdr1p, a multi-drug transporter of Candida albicans, belonging to the ATP binding cassette super family. FEMS Microbiol. Lett., 158, 69-74 (1998).
14. Maesaki S, Marichal P, Vanden Bossche H, Sanglard D, Kohno S. Rhodamine 6G efflux for the detection of CDR1-overexpressing azole-resistant Candida albicans strains. J. Antimicrob. Chemother., 44, 27-31 (1999).
15. de Micheli M, Bille J, Schueller C, Sanglard D. A common drug-responsive element mediates the upregulation of the Candida albicans ABC transporters CDR1 and CDR2, two genes involved in antifungal drug resistance. Mol. Microbiol., 43, 1197-1214 (2002).
16. Coste AT, Karababa M, Ischer F, Bille J, Sanglard D. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot. Cell, 3, 1639-1652 (2004).
17. MacPherson S, Larochelle M, Turcotte B. A fungal family of transcriptional regulators. the zinc cluster proteins. Microbiol. Mol. Biol. Rev., 70, 583-604 (2006).
18. Mantena SK, Sharma SD, Katiyar SK. Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol. Cancer Ther., 5, 296-308 (2006).
19. Ficker CE, Arnason JT, Vindas PS, Alvarez LP, Akpagana K, Gbeassor M, De Souza C, Smith ML. Inhibition of human pathogenic fungi by ethnobotanically selected plant extracts. Mycoses, 46, 29-37 (2003).
20. Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother. Res., 22, 999-1012 (2008).
21. Han Y, Lee JH. Berberine synergy with amphotericin B against disseminated candidiasis in mice. Biol. Pharm. Bull., 28, 541-544 (2005).
22. Wei G-X, Xu X, Wu CD. In vitro synergism between berberine and miconazole against planktonic and biofilm Candida cultures. Arch. Oral Biol., 56, 565-572 (2011).
23. Iwazaki RS, Endo EH, Ueda-Nakamura T, Nakamura CV, Garcia LB, Filho BP. In vitro antifungal activity of the berberine and its synergism with fluconazole. Antonie van Leeuwenhoek, 97, 201-205 (2010).
24. Quan H, Cao Y-Y, Xu Z, Zhao J-X, Gao P-H, Qin X-F, Jiang Y-Y. Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole. Antimicrob. Agents Chemother., 50, 1096-1099 (2006).
25. Davidson MW, Lopp I, Alexander S, Wilson WD. The interaction of plant alkaloids with DNA. II. Berberinium chloride. Nucleic Acids Res., 4, 2697-2712 (1977).
26. Debnath D, Kumar GS, Nandi R, Maiti M. Interaction of berberine chloride with deoxyribonucleic acids: evidence for base and sequence specificity. Indian J. Biochem. Biophys., 26, 201-208 (1989).
27. Saran A, Srivastava S, Coutinho E, Maiti M. 1H NMR investigation of the interaction of berberine and sanguinarine with DNA. Indian J. Biochem. Biophys., 32, 74-77 (1995).
28. Bhadra K, Maiti M, Kumar GS. Berberine-DNA complexation: New insights into the cooperative binding and energetic aspects. Biochim. Biophys. Acta, 1780, 1054-1061 (2008).
29. Saidane S, Weber S, De Deken X, St-Germain G, Raymond M. PDR16-mediated azole resistance in Candida albicans. Mol. Microbiol., 60, 1546-1562 (2006).
30. Yan L, Cote P, Li XX, Jiang YY, Whiteway M. PalI domain proteins of Saccharomyces cerevisiae and Candida albicans. Microbiol. Res., 167, 422-432 (2012).
31. Yan L, Zhang J, Li M, Cao Y, Xu Z, Cao Y, Gao P, Wang Y, Jiang Y. DNA microarray analysis of fluconazole resistance in a laboratory Candida albicans strain. Acta Biochim. Biophys. Sin. (Shanghai), 40, 1048-1060 (2008).
32. Wang Z, Guo X, Liu Z, Cui M, Song F, Liu S. Studies on alkaloids binding to GC-rich human survivin promoter DNA using positive and negative ion electrospray ionization mass spectrometry. J. Mass Spectrom., 43, 327-335 (2008).
33. Xu Y, Wang Y, Yan L, Liang RM, Dai BD, Tang RJ, Gao PH, Jiang YY. Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: endogenous ROS augmentation. J. Proteome Res., 8, 5296-5304 (2009).
34. Zhu SL, Jiang ZH, Gao PH, Qiu Y, Wang L, Jiang YH, Zhang DZ. A novel polyamide SL-A92 as a potential fungal resistance blocker: synthesis and bioactivities in Candida albicans. Acta Pharmacol. Sin., 31, 855-860 (2010).